Physician profile
Thomas A Hope
NPI 1093040123
$105,302.82
in general payments reported to CMS, 2019-2025
20 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Nuclear Radiology providers received nationally (typical 2025 total: $145).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,737 · 2020: $19K · 2021: $13K · 2022: $16K · 2023: $8,033 · 2024: $14K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Travel and Lodging: $4,062 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,940 · Food and Beverage: $1,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,733.02 |
| Travel and Lodging | $4,061.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,940.00 |
| Food and Beverage | $1,948.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curium US LLC | $31,198.91 | 2019-2025 | Detectnet |
| E.R. Squibb & Sons, L.L.C. | $18,674.09 | 2024-2025 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $14,867.64 | 2021-2023 | |
| Ipsen Bioscience INC. | $7,200.00 | 2020 | |
| Progenics Pharmaceuticals, INC. | $6,637.09 | 2019-2023 | Pylarify |
| Advanced Accelerator Applications | $6,177.51 | 2019-2020 | |
| Cardinal Health 414 LLC | $4,500.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $3,915.81 | 2023-2025 | |
| Genzyme Corporation | $3,570.74 | 2019-2024 | |
| Lantheus Medical Imaging, INC. | $2,940.00 | 2025 | |
| Blue Earth Diagnostics | $2,533.79 | 2020-2025 | Posluma |
| Astrazeneca Uk Limited | $2,148.00 | 2025 | |
| Ge Healthcare | $332.65 | 2019-2025 | |
| Siemens Medical Solutions USA, INC. | $174.21 | 2023 | |
| Clovis Oncology, INC. | $146.28 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $124.86 | 2023 | Cabenuva |
| Telix Pharmaceuticals | $100.32 | 2022-2024 | Illuccix |
| United Imaging Healthcare North America LLC | $30.92 | 2024 | Pet-Mr |
| Amgen INC. | $30.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.